featured
Efficacy and Safety of Fedratinib in Patients With Myelofibrosis Previously Treated With Ruxolitinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
Lancet Haematol 2024 Sep 09;[EPub Ahead of Print], CN Harrison, R Mesa, M Talpaz, HK Al-Ali, B Xicoy, F Passamonti, F Palandri, G Benevolo, AM Vannucchi, C Mediavilla, A Iurlo, I Kim, S Rose, P Brown, C Hernandez, J Wang, JJ KiladjianFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.